Showing results (1461-1470 of 1,497) with videos related to
Sort By:
Pageof 150
Bioorganic & Medicinal Chemistry Letters|November 15, 2011
The discovery of non-benzimidazole and brain-penetrant prolylcarboxypeptidase inhibitorsThomas H Graham, Hong C Shen, Wensheng Liu, et al.Journal of Medicinal Chemistry|March 4, 2025
Discovery of DFV890, a Potent Sulfonimidamide-Containing NLRP3 Inflammasome InhibitorDong-Ming Shen, Kate F Byth, Damien Bertheloot, et al.JAMA Oncology|December 21, 2023
Whole-Brain Radiotherapy Alone vs Preceded by Bevacizumab, Etoposide, and Cisplatin for Untreated Brain Metastases From Breast Cancer: A Randomized Clinical TrialTom Wei-Wu Chen, Ming-Shen Dai, Ling-Ming Tseng, et al.Journal of Medicinal Chemistry|March 3, 2017
Microscale High-Throughput Experimentation as an Enabling Technology in Drug Discovery: Application in the Discovery of (Piperidinyl)pyridinyl-1H-benzimidazole Diacylglycerol Acyltransferase 1 InhibitorsTim Cernak, Nathan J Gesmundo, Kevin Dykstra, et al.Journal of Hepatology|April 26, 2024
Targeting EFHD2 inhibits interferon-γ signaling and ameliorates non-alcoholic steatohepatitisJiang-Tao Fu, Jian Liu, Wen-Bin Wu, et al.Journal of Medicinal Chemistry|January 21, 2014
Design, synthesis, and evaluation of conformationally restricted acetanilides as potent and selective β3 adrenergic receptor agonists for the treatment of overactive bladderChristopher R Moyes, Richard Berger, Stephen D Goble, et al.Translational Breast Cancer Research : a Journal Focusing on Translational Research in Breast Cancer|May 16, 2024
Efficacy and safety of margetuximab plus chemotherapy vs. trastuzumab plus chemotherapy in Chinese patients with pretreated HER2-positive advanced metastatic breast cancer: results from a randomized, open-label, multicenter, phase II bridging studyQingyuan Zhang, Quchang Ouyang, Wei Li, et al.European Journal of Endocrinology|February 2, 2018
The comprehensive impact on human body induced by resolution of growth hormone excessZhaoyun Zhang, Qin Li, Wenqiang He, et al.Bioorganic & Medicinal Chemistry Letters|March 12, 2004
Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 3: SAR studies on the benzylpyrazole segmentMin Shu, Jennifer L Loebach, Kerry A Parker, et al.Bioorganic & Medicinal Chemistry Letters|March 12, 2004
Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 2: Discovery of potent, selective, and orally bioavailable compoundsDong-Ming Shen, Min Shu, Christopher A Willoughby, et al.Pageof 150